메뉴 건너뛰기




Volumn 9, Issue 2, 2014, Pages

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: Results of a phase i study

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EXPORTIN 1; KPT 335; PREDNISONE; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; HYDRAZINE DERIVATIVE; KPT-335;

EID: 84895173747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087585     Document Type: Article
Times cited : (81)

References (46)
  • 1
    • 84862501107 scopus 로고    scopus 로고
    • The CRM1 nuclear export protein in normal development and disease
    • Nguyen KT, Holloway MP, Altura RA (2012) The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 3: 137-151.
    • (2012) Int J Biochem Mol Biol , vol.3 , pp. 137-151
    • Nguyen, K.T.1    Holloway, M.P.2    Altura, R.A.3
  • 2
    • 84858005605 scopus 로고    scopus 로고
    • Nuclear export of proteins and drug resistance in cancer
    • Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83: 1021-1032.
    • (2012) Biochem Pharmacol , vol.83 , pp. 1021-1032
    • Turner, J.G.1    Dawson, J.2    Sullivan, D.M.3
  • 3
    • 61649105802 scopus 로고    scopus 로고
    • CRM1-mediated nuclear export of proteins and drug resistance in cancer
    • Turner JG, Sullivan DM (2008) CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15: 2648-2655.
    • (2008) Curr Med Chem , vol.15 , pp. 2648-2655
    • Turner, J.G.1    Sullivan, D.M.2
  • 4
    • 84866422549 scopus 로고    scopus 로고
    • NESdb: A database of NES-containing CRM1 cargoes
    • Xu D, Grishin NV, Chook YM (2012) NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 23: 3673-3676.
    • (2012) Mol Biol Cell , vol.23 , pp. 3673-3676
    • Xu, D.1    Grishin, N.V.2    Chook, Y.M.3
  • 5
    • 80052230265 scopus 로고    scopus 로고
    • Ran-dependent nuclear export mediators: A structural perspective
    • Guttler T, Gorlich D (2011) Ran-dependent nuclear export mediators: a structural perspective. EMBO J 30: 3457-3474.
    • (2011) EMBO J , vol.30 , pp. 3457-3474
    • Guttler, T.1    Gorlich, D.2
  • 6
    • 11844272621 scopus 로고    scopus 로고
    • Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo
    • DOI 10.1128/MCB.25.2.728-739.2005
    • Daelemans D, Costes SV, Lockett S, Pavlakis GN (2005) Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo. Mol Cell Biol 25: 728-739. (Pubitemid 40096593)
    • (2005) Molecular and Cellular Biology , vol.25 , Issue.2 , pp. 728-739
    • Daelemans, D.1    Costes, S.V.2    Lockett, S.3    Pavlakis, G.N.4
  • 7
    • 0030924190 scopus 로고    scopus 로고
    • CRM1 is an export receptor for leucine-rich nuclear export signals
    • DOI 10.1016/S0092-8674(00)80371-2
    • Fornerod M, Ohno M, Yoshida M, Mattaj IW (1997) CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051-1060. (Pubitemid 27408519)
    • (1997) Cell , vol.90 , Issue.6 , pp. 1051-1060
    • Fornerod, M.1    Ohno, M.2    Yoshida, M.3    Mattaj, I.W.4
  • 8
    • 84891851776 scopus 로고    scopus 로고
    • CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications
    • Epub ahead of print
    • Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, et al. (2013) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia Epub ahead of print.
    • (2013) Leukemia
    • Tai, Y.T.1    Landesman, Y.2    Acharya, C.3    Calle, Y.4    Zhong, M.Y.5
  • 11
    • 58349104143 scopus 로고    scopus 로고
    • Identification of nuclear export inhibitors with potent anticancer activity in vivo
    • Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, et al. (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69: 510-517.
    • (2009) Cancer Res , vol.69 , pp. 510-517
    • Mutka, S.C.1    Yang, W.Q.2    Dong, S.D.3    Ward, S.L.4    Craig, D.A.5
  • 12
    • 84881323214 scopus 로고    scopus 로고
    • Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice
    • Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, et al. (2012) Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice. Gastroenterology 144: 447-456.
    • (2012) Gastroenterology , vol.144 , pp. 447-456
    • Azmi, A.S.1    Aboukameel, A.2    Bao, B.3    Sarkar, F.H.4    Philip, P.A.5
  • 13
    • 84858004491 scopus 로고    scopus 로고
    • Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells
    • Draetta GG, Shacham S, Kauffman M, Sandanayaka V, Schechter S, et al. (2011) Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells. J Clin Oncol 29: e14091.
    • (2011) J Clin Oncol , vol.29
    • Draetta, G.G.1    Shacham, S.2    Kauffman, M.3    Sandanayaka, V.4    Schechter, S.5
  • 14
    • 84875052270 scopus 로고    scopus 로고
    • KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective antileukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
    • Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, et al. (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective antileukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 161: 117-127.
    • (2013) Br J Haematol , vol.161 , pp. 117-127
    • Etchin, J.1    Sanda, T.2    Mansour, M.R.3    Kentsis, A.4    Montero, J.5
  • 15
    • 84870502798 scopus 로고    scopus 로고
    • Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
    • Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, et al. (2012) Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120: 4621-4634.
    • (2012) Blood , vol.120 , pp. 4621-4634
    • Lapalombella, R.1    Sun, Q.2    Williams, K.3    Tangeman, L.4    Jha, S.5
  • 16
    • 84872427339 scopus 로고    scopus 로고
    • Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC)
    • Abstract 1055
    • McCauley D, Landesman Y, Senapedis W, Kashyap T, Saint-Martin J-R, et al. (2012) Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). J Clin Oncol 30 Suppl: Abstract 1055.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • McCauley, D.1    Landesman, Y.2    Senapedis, W.3    Kashyap, T.4    Saint-Martin, J.-R.5
  • 17
    • 84865749132 scopus 로고    scopus 로고
    • Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
    • Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, et al. (2012) Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120: 1765-1773.
    • (2012) Blood , vol.120 , pp. 1765-1773
    • Ranganathan, P.1    Yu, X.2    Na, C.3    Santhanam, R.4    Shacham, S.5
  • 18
    • 84870887672 scopus 로고    scopus 로고
    • Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma
    • Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, et al. (2013) Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41: 67-78 e64.
    • (2013) Exp Hematol , vol.41
    • Zhang, K.1    Wang, M.2    Tamayo, A.T.3    Shacham, S.4    Kauffman, M.5
  • 19
    • 84873570648 scopus 로고    scopus 로고
    • Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
    • Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, et al. (2013) Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27: 66-74.
    • (2013) Leukemia , vol.27 , pp. 66-74
    • Etchin, J.1    Sun, Q.2    Kentsis, A.3    Farmer, A.4    Zhang, Z.C.5
  • 20
    • 84877601009 scopus 로고    scopus 로고
    • CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth
    • Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, et al. (2013) CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth. J Urol 189: 2317-2326.
    • (2013) J Urol , vol.189 , pp. 2317-2326
    • Inoue, H.1    Kauffman, M.2    Shacham, S.3    Landesman, Y.4    Yang, J.5
  • 23
    • 66149168682 scopus 로고    scopus 로고
    • Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma
    • Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, et al. (2009) Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res 15: 3503-3510.
    • (2009) Clin Cancer Res , vol.15 , pp. 3503-3510
    • Vail, D.M.1    Thamm, D.H.2    Reiser, H.3    Ray, A.S.4    Wolfgang, G.H.5
  • 24
    • 77955625479 scopus 로고    scopus 로고
    • The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
    • Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107: 13075-13080.
    • (2010) Proc Natl Acad Sci U S a , vol.107 , pp. 13075-13080
    • Honigberg, L.A.1    Smith, A.M.2    Sirisawad, M.3    Verner, E.4    Loury, D.5
  • 25
    • 80455174301 scopus 로고    scopus 로고
    • Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
    • London CA, Bear MD, McCleese J, Foley KP, Paalangara R, et al. (2011) Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer. PLoS One 6: e27018.
    • (2011) PLoS One , vol.6
    • London, C.A.1    Bear, M.D.2    McCleese, J.3    Foley, K.P.4    Paalangara, R.5
  • 26
    • 84862743178 scopus 로고    scopus 로고
    • CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: A tool for in vitro preclinical studies with primary B-cell malignancies
    • Ito D, Frantz AM, Williams C, Thomas R, Burnett RC, et al. (2012) CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma 53: 1390-1398.
    • (2012) Leuk Lymphoma , vol.53 , pp. 1390-1398
    • Ito, D.1    Frantz, A.M.2    Williams, C.3    Thomas, R.4    Burnett, R.C.5
  • 28
    • 77952959216 scopus 로고    scopus 로고
    • Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma
    • Rutgen BC, Hammer SE, Gerner W, Christian M, de Arespacochaga AG, et al. (2010) Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 34: 932-938.
    • (2010) Leuk Res , vol.34 , pp. 932-938
    • Rutgen, B.C.1    Hammer, S.E.2    Gerner, W.3    Christian, M.4    De Arespacochaga, A.G.5
  • 29
    • 84862993855 scopus 로고    scopus 로고
    • Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model
    • Rutgen BC, Willenbrock S, Reimann-Berg N, Walter I, Fuchs-Baumgartinger A, et al. (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model. PLoS One 7: e40078.
    • (2012) PLoS One , vol.7
    • Rutgen, B.C.1    Willenbrock, S.2    Reimann-Berg, N.3    Walter, I.4    Fuchs-Baumgartinger, A.5
  • 31
    • 0025936536 scopus 로고
    • Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3
    • Yee CS, Messner HA, Minden MD (1991) Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J Cell Physiol 148: 426-429. (Pubitemid 21926078)
    • (1991) Journal of Cellular Physiology , vol.148 , Issue.3 , pp. 426-429
    • Yee, C.S.1    Messner, H.A.2    Minden, M.D.3
  • 32
    • 23744437996 scopus 로고    scopus 로고
    • c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells
    • DOI 10.1182/blood-2004-10-3819
    • Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, et al. (2005) c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391. (Pubitemid 41129605)
    • (2005) Blood , vol.106 , Issue.4 , pp. 1382-1391
    • Gururajan, M.1    Chui, R.2    Karuppannan, A.K.3    Ke, J.4    Jennings, C.D.5    Bondada, S.6
  • 33
    • 0025514349 scopus 로고
    • Establishment of two dog mastocytoma cell lines in continuous culture
    • DeVinney R, Gold WM (1990) Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 3: 413-420.
    • (1990) Am J Respir Cell Mol Biol , vol.3 , pp. 413-420
    • DeVinney, R.1    Gold, W.M.2
  • 34
    • 77956638515 scopus 로고    scopus 로고
    • Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro
    • McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA (2010) Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. Am J Vet Res 71: 799-808.
    • (2010) Am J Vet Res , vol.71 , pp. 799-808
    • McMahon, M.B.1    Bear, M.D.2    Kulp, S.K.3    Pennell, M.L.4    London, C.A.5
  • 36
    • 85048701331 scopus 로고    scopus 로고
    • Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1
    • Epub ahead of print
    • (2011) Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol Epub ahead of print.
    • (2011) Vet Comp Oncol
  • 37
    • 75249085780 scopus 로고    scopus 로고
    • Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document
    • Vail DM, Michels GM, Khanna C, Selting KA, London CA (2010) Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 8: 28-37.
    • (2010) Vet Comp Oncol , vol.8 , pp. 28-37
    • Vail, D.M.1    Michels, G.M.2    Khanna, C.3    Selting, K.A.4    London, C.A.5
  • 38
    • 80051750421 scopus 로고    scopus 로고
    • Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer
    • Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ (2011) Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol 9: 172-182.
    • (2011) Vet Comp Oncol , vol.9 , pp. 172-182
    • Lynch, S.1    Savary-Bataille, K.2    Leeuw, B.3    Argyle, D.J.4
  • 39
    • 0030880605 scopus 로고    scopus 로고
    • Small sample inference for fixed effects from restricted maximum likelihood
    • DOI 10.2307/2533558
    • Kenward MG, Roger JH (1997) Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53: 983-997. (Pubitemid 27391027)
    • (1997) Biometrics , vol.53 , Issue.3 , pp. 983-997
    • Kenward, M.G.1    Roger, J.H.2
  • 40
    • 84866414249 scopus 로고    scopus 로고
    • Sequence and structural analyses of nuclear export signals in the NESdb database
    • Xu D, Farmer A, Collett G, Grishin NV, Chook YM (2012) Sequence and structural analyses of nuclear export signals in the NESdb database. Mol Biol Cell 23: 3677-3693.
    • (2012) Mol Biol Cell , vol.23 , pp. 3677-3693
    • Xu, D.1    Farmer, A.2    Collett, G.3    Grishin, N.V.4    Chook, Y.M.5
  • 41
    • 0030831534 scopus 로고    scopus 로고
    • CRM1 is responsible for intracellular transport mediated by the nuclear export signal
    • DOI 10.1038/36894
    • Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, et al. (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308-311. (Pubitemid 27513316)
    • (1997) Nature , vol.390 , Issue.6657 , pp. 308-311
    • Fukuda, M.1    Asano, S.2    Nakamura, T.3    Adachi, M.4    Yoshida, M.5    Yanagida, M.6    Nishida, E.7
  • 42
    • 33845611951 scopus 로고    scopus 로고
    • Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
    • DOI 10.1016/j.cell.2006.12.007, PII S0092867406015972
    • Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334. (Pubitemid 44960417)
    • (2006) Cell , vol.127 , Issue.7 , pp. 1323-1334
    • Martins, C.P.1    Brown-Swigart, L.2    Evan, G.I.3
  • 44
    • 80053619765 scopus 로고    scopus 로고
    • CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
    • Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, et al. (2011) CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118: 3922-3931.
    • (2011) Blood , vol.118 , pp. 3922-3931
    • Sakakibara, K.1    Saito, N.2    Sato, T.3    Suzuki, A.4    Hasegawa, Y.5
  • 45
    • 84879566083 scopus 로고    scopus 로고
    • Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas
    • Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, et al. (2013) Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica 98: 1098-1106.
    • (2013) Haematologica , vol.98 , pp. 1098-1106
    • Azmi, A.S.1    Al-Katib, A.2    Aboukameel, A.3    McCauley, D.4    Kauffman, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.